Recent preclinical studies targeting activating pathway in PEL
Study ref. . | Drug . | Activity . | Model . | Key findings . |
---|---|---|---|---|
77 | Berberine | NF-κB inhibition | In vitro: PEL cell lines | Induction of apoptosis and suppressed NF-κB activity by inhibiting IKK phosphorylation |
In vivo: xenograft mouse model | ||||
83 | Thioridazine | MALT1 inhibition | In vitro: PEL cell lines | MALT1 inhibition induced a switch to lytic phase and the reduced growth and survival |
In vivo: xenograft mouse model | ||||
78 | 3-AP | Ribonucleotide reductase inhibition | In vitro: PEL cell lines | Induction of cell cycle arrest through the inhibition of NF-κB pathway |
In vivo: xenograft mouse model | ||||
88 | PEP005 | Agonist of protein kinase C and activation of NF-κB | In vitro: PEL cell lines | Combination of PEP005 with BET inhibitor induced HHV8/KSHV lytic replication and the inhibition of IL6 production |
91 | PF-04691502, AKTi 1/2 | PI3K/AKT/mTOR inhibition | In vitro: PEL cell lines | Combination of PI3K/AKT/mTOR inhibitor with a glycolytic inhibitor strengthened the cytotoxicity in PEL cells |
89 | PF-2341066 | c-MET inhibition | In vitro: PEL cell lines | Induction of G2/M cell cycle arrest and apoptosis of PEL cells in vitro and in vivo |
79 | Everolimus | mTOR inhibition | In vitro: PEL cell lines | Induction of caspase-dependent apoptosis and downregulation of HHV8/KSHV latent antigen expression |
93 | Tenovin-6 | SIRT1 and SIRT2 inhibition | In vitro: PEL cell lines | Inhibition of cell proliferation and induction of apoptosis through AMPK inactivation |
In vivo: xenograft mouse model | ||||
80 | ABC294640 | Sphingosine kinase 2 inhibition | In vitro: PEL cell lines | Induction of apoptosis through the suppression of HHV8/KSHV-associated signal transduction |
In vivo: xenograft mouse model | ||||
81 | MLN4924 | Neddylation inhibitor | In vitro: PEL cell lines | Induction of viral lytic protein expression |
94 | YM155 | Survivin inhibition | In vitro: PEL cell line; PDX cell | Induction of apoptosis through the decreased MCL1 expression |
In vivo: PDX mouse model | ||||
90 | PX-478 | HIF-1α inhibition | In vitro: PEL cell lines | Induction of a dose-dependent decrease in HIF-1α mRNA and reduction of cell proliferation |
92 | Metformin | Reduction of intracellular ROS | In vitro: PEL cell lines | Induction of apoptosis through the downregulation of v-FLIP, the reduction of intracellular ROS, the activation of AMPK, the inhibition of mTOR, and the dephosphorylation of STAT3 |
82 | Chloroquine | ER stress activation | In vitro: PEL cell lines | Induction of ER stress-mediated apoptosis |
In vivo: xenograft mouse model | ||||
87 | IMiDs | Immunomodulation | In vitro: PEL cell lines | Preventing HHV8/KSHV-induced downregulation of MHC-1 surface expression |
86 | IMiDs | IKZF-IRF4-MYC axis inhibition | In vitro: PEL cell lines | Induction of cell cycle arrest resulting in the suppression of IRF4 and the rapid degradation of IKZF1, but not IKZF3 |
In vivo: xenograft mouse model |
Study ref. . | Drug . | Activity . | Model . | Key findings . |
---|---|---|---|---|
77 | Berberine | NF-κB inhibition | In vitro: PEL cell lines | Induction of apoptosis and suppressed NF-κB activity by inhibiting IKK phosphorylation |
In vivo: xenograft mouse model | ||||
83 | Thioridazine | MALT1 inhibition | In vitro: PEL cell lines | MALT1 inhibition induced a switch to lytic phase and the reduced growth and survival |
In vivo: xenograft mouse model | ||||
78 | 3-AP | Ribonucleotide reductase inhibition | In vitro: PEL cell lines | Induction of cell cycle arrest through the inhibition of NF-κB pathway |
In vivo: xenograft mouse model | ||||
88 | PEP005 | Agonist of protein kinase C and activation of NF-κB | In vitro: PEL cell lines | Combination of PEP005 with BET inhibitor induced HHV8/KSHV lytic replication and the inhibition of IL6 production |
91 | PF-04691502, AKTi 1/2 | PI3K/AKT/mTOR inhibition | In vitro: PEL cell lines | Combination of PI3K/AKT/mTOR inhibitor with a glycolytic inhibitor strengthened the cytotoxicity in PEL cells |
89 | PF-2341066 | c-MET inhibition | In vitro: PEL cell lines | Induction of G2/M cell cycle arrest and apoptosis of PEL cells in vitro and in vivo |
79 | Everolimus | mTOR inhibition | In vitro: PEL cell lines | Induction of caspase-dependent apoptosis and downregulation of HHV8/KSHV latent antigen expression |
93 | Tenovin-6 | SIRT1 and SIRT2 inhibition | In vitro: PEL cell lines | Inhibition of cell proliferation and induction of apoptosis through AMPK inactivation |
In vivo: xenograft mouse model | ||||
80 | ABC294640 | Sphingosine kinase 2 inhibition | In vitro: PEL cell lines | Induction of apoptosis through the suppression of HHV8/KSHV-associated signal transduction |
In vivo: xenograft mouse model | ||||
81 | MLN4924 | Neddylation inhibitor | In vitro: PEL cell lines | Induction of viral lytic protein expression |
94 | YM155 | Survivin inhibition | In vitro: PEL cell line; PDX cell | Induction of apoptosis through the decreased MCL1 expression |
In vivo: PDX mouse model | ||||
90 | PX-478 | HIF-1α inhibition | In vitro: PEL cell lines | Induction of a dose-dependent decrease in HIF-1α mRNA and reduction of cell proliferation |
92 | Metformin | Reduction of intracellular ROS | In vitro: PEL cell lines | Induction of apoptosis through the downregulation of v-FLIP, the reduction of intracellular ROS, the activation of AMPK, the inhibition of mTOR, and the dephosphorylation of STAT3 |
82 | Chloroquine | ER stress activation | In vitro: PEL cell lines | Induction of ER stress-mediated apoptosis |
In vivo: xenograft mouse model | ||||
87 | IMiDs | Immunomodulation | In vitro: PEL cell lines | Preventing HHV8/KSHV-induced downregulation of MHC-1 surface expression |
86 | IMiDs | IKZF-IRF4-MYC axis inhibition | In vitro: PEL cell lines | Induction of cell cycle arrest resulting in the suppression of IRF4 and the rapid degradation of IKZF1, but not IKZF3 |
In vivo: xenograft mouse model |
3-AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; AMPK, adenosine monophosphate–activated protein kinase; BET, bromodomain and extraterminal; ER, endoplasmic reticulum; IKZF, Ikaros family zinc finger protein; IMiD, immunomodulatory drug; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; MCL1, myeloid cell leukemia 1; PDX, patient-derived xenograft; ROS, reactive oxygen species.